Does chemoimmunotherapy still have a role in CLL?: Chemoimmunotherapy with FCR is still an important option in CLL

Does chemoimmunotherapy still have a role in CLL? Chemoimmunotherapy with FCR is still an important option in CLL

Research output: Contribution to journal › Comment / Debate › Other › peer-review

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{246b93859ccd4306837e1b50fcbf1b77,

title = "Does chemoimmunotherapy still have a role in CLL?: Chemoimmunotherapy with FCR is still an important option in CLL",

author = "Thompson, \{Philip A.\} and Tam, \{Constantine S.\}",

year = "2018",

month = jun,

day = "15",

language = "English",

volume = "32",

pages = "291--296",

journal = "Oncology",

issn = "0890-9091",

publisher = "Cancer Network",

number = "6",

}

TY - JOUR

T1 - Does chemoimmunotherapy still have a role in CLL?

T2 - Chemoimmunotherapy with FCR is still an important option in CLL

AU - Thompson, Philip A.

AU - Tam, Constantine S.

PY - 2018/6/15

Y1 - 2018/6/15

UR - https://www.scopus.com/pages/publications/85053070688

M3 - Comment / Debate

C2 - 29940059

AN - SCOPUS:85053070688

SN - 0890-9091

VL - 32

SP - 291

EP - 296

JO - Oncology

JF - Oncology

IS - 6

ER -